Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4777267 | 0.94 | PARP1 (0.44) | PARP1NPC1RAB9APARP2SMN1; SMN2 | |
| SCHEMBL4779565 | 0.92 | PARP1 (0.49) | PARP1PARP2SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL4773072 | 0.84 | ALDH1A1 (0.40) | PARP1NPC1RAB9APARP2SMN1; SMN2 | |
| SCHEMBL13987164 | 0.83 | PARP1 (0.43) | PARP1PARP2KDM4EALDH1A1MAPT | |
| SCHEMBL4793556 | 0.83 | PARP1 (0.39) | PARP1NPC1RAB9APARP2ALDH1A1 | |
| SCHEMBL4778618 | 0.81 | ROCK2 (0.41) | PARP1PARP2ALDH1A1ROCK2ROCK1 | |
| SCHEMBL4777119 | 0.81 | NPC1 (0.44) | PARP1NPC1PARP2ROCK2ROCK1 | |
| SCHEMBL4778270 | 0.80 | NPC1 (0.44) | PARP1NPC1RAB9APARP2SMN1; SMN2 | |
| SCHEMBL4815268 | 0.76 | PAK4 (0.44) | PARP1PARP2ROCK2ROCK1CDK2 | |
| SCHEMBL4774689 | 0.76 | IMPDH2 (0.47) | PARP1PARP2KDM4EROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075499-A1 | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy | AGOURON PHARMACEUTICALS, INC. | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075499-A1 | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy | CHEK2, CHEK1, CHKA | PARP1 628/4885NPC1 1034/4885RAB9A 2019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.